Table 1

Effect of end-induction MRD on outcome by therapeutic protocol and NCI risk group

Study/risk group5-y EFS, % ± SE (no.)
MRD−MRD+ (> .01%)*
9904/SR 95 ± 1 (668) 64 ± 7 (105) 
9905/SR 89 ± 2 (464) 59 ± 6 (119) 
9905/HR 79 ± 4 (295) 33 ± 8 (74) 
9906/HR† 72 ± 5 (161) 34 ± 8 (85) 
Study/risk group5-y EFS, % ± SE (no.)
MRD−MRD+ (> .01%)*
9904/SR 95 ± 1 (668) 64 ± 7 (105) 
9905/SR 89 ± 2 (464) 59 ± 6 (119) 
9905/HR 79 ± 4 (295) 33 ± 8 (74) 
9906/HR† 72 ± 5 (161) 34 ± 8 (85) 
*

P < .001 for all comparisons.

†

Also includes CNS3 patients, patients with testicular disease, or patients with MLL rearrangements.

View Large